BISHOPS STORTFORD, England--(EON: Enhanced Online News)--Dotmatics announced today that it has seamlessly integrated data analysis and visualization solution Vortex with Thomson Reuters’ Cortellis®, the industry’s premier Life Sciences information delivery platform. Scientists can now use Vortex to directly retrieve data from Cortellis and combine it with their own, in-house records to gain new insights into their research. The combination of the powerful analytic tools of Vortex, high quality drug, patent and market information from Thomson Reuters’ Cortellis with home-grown data guarantees that scientists can promptly find critical intelligence to make effective, evidence-based decisions.
“Following customer requests we’ve developed a module that enables users to query Cortellis directly from Vortex. Users can then combine results from this search with their own data. This data mash-up can be done very rapidly, providing a unique insight into the research target”
Vortex is a data analysis and visualization platform that has chemical structure intelligence whilst Cortellis provides an integrated view into Thomson Reuters’ pharmaceutical data content. The accessible and graphical interface within Vortex makes for easy data analysis across all data types whilst providing users with a unique and novel way to view their data.
“Following customer requests we’ve developed a module that enables users to query Cortellis directly from Vortex. Users can then combine results from this search with their own data. This data mash-up can be done very rapidly, providing a unique insight into the research target,” said Dr. Mike Hartshorn, CSO at Dotmatics. “Vortex undoubtedly provides an easy way to analyse and visualize complex data derived from multiple data sources and makes Cortellis an integral part of researchers’ daily activity.”
“We are pleased to make the industry leading drug, market and intellectual property information from Thomson Reuters available to Dotmatics users for deeper insight into the data,” said Joe Donahue, Senior Vice President at Thomson Reuters. “The graphic interfaces allow researchers to more effectively identify the essential data needed in drug discovery, leading to stronger and faster decision-making.”
At the forefront of innovation, Dotmatics is a leading global scientific informatics software and services provider, delivering solutions tailored to the modern, highly collaborative and mobile pharmaceutical, biotechnology and chemical industries as well as academia. Dotmatics’ enterprise solutions are flexible, scalable and configurable, providing effective scientific information management across entire organizations, from discovery research to development and early manufacturing. Dotmatics has significant expertise in scientific informatics, including database management for chemistry and biologics, electronic laboratory notebooks, chemical and biological registration, screening data management, SAR analysis, reporting, and visualization. Dotmatics solutions are available for local or cloud deployment and they are supported on Microsoft Windows, MAC OS X and Linux. A privately owned company, Dotmatics was founded in 2005 and their headquarters is based south of Cambridge in the UK.
About Thomson Reuters: Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minn., Thomson Reuters employs approximately 60,000 people and operates in over 100 countries. Thomson Reuters shares are listed on the Toronto and New York Stock Exchanges. For more information, go to www.thomsonreuters.com. Learn more about Thomson Reuters Cortellis. Follow Cortellis (@Cortellis) on Twitter for the latest news in drug discovery, development, regulatory, commercialization, forecast and generics intelligence.